Drug Co-Marketed by Bristol-Myers and Sanofi

By Published on .

DETROIT ( -- Pharmaceutical makers Bristol-Myers Squibb and Sanofi-Synthelabo have awarded their co-marketed $70 million Plavix account to Publicis Groupe's Saatchi & Saatchi Healthcare, a Bristol-Myers spokesman said.

Plavix is a prescription blood-thinning medication. It competes with several anticoagulants, as well as traditional aspirin.

Executives from Saatchi & Saatchi could not be reached.

Saatchi & Saatchi Healthcare beat out [email protected] JWT, a unit of WPP Group's J. Walter Thompson; Omnicom Group's DDB Worldwide; Grey Global Group's Grey Healthcare; and Havas' Euro RSCG MVBMS Partners, all New York-based agencies.

WPP's Ogilvy & Mather resigned the business in December.

Plavix represents the second big account win for Saatchi & Saatchi Healthcare in the last four weeks. Last month, the agency won the osteoporosis drug Boniva, co-marketed by Roche and GlaxoSmithKline.

Most Popular